What is Tomefloxacin used for?

Tomefloxacin is indicated for Acute Moraxella catarrhalis bronchitis, Acute bacterial bronchitis, Acute gonococcal cervicitis, Chlamydia Cervicitis, Gonorrhea.

Who makes Tomefloxacin?

Tomefloxacin is developed by Otsuka.

What development phase is Tomefloxacin in?

Tomefloxacin is FDA-approved (marketed).

What is the generic name of Tomefloxacin?

GREPAFLOXACIN is the generic (nonproprietary) name of Tomefloxacin.

Last reviewed 2026-04-20 · How we verify

Tomefloxacin (GREPAFLOXACIN)

Otsuka · FDA-approved withdrawn Small molecule Quality 35/100

Tomefloxacin, also known as Grepafloxacin, is a small molecule antibiotic developed by OTSUKA and approved by the FDA in 1997. It targets the potassium voltage-gated channel subfamily H member 2 and is used to treat various bacterial infections, including bronchitis, pneumonia, and gonorrhea. As an off-patent medication, it is no longer protected by active patents, but there are currently no generic manufacturers. The medication has a bioavailability of 70% and a half-life of 9.2 hours. It is used to treat a range of bacterial infections, but its commercial status is limited due to the lack of generic competition.

At a glance

Generic name	GREPAFLOXACIN
Sponsor	Otsuka
Drug class	grepafloxacin
Target	Potassium voltage-gated channel subfamily H member 2
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	FDA-approved
First approval	1997

Approved indications

Acute Moraxella catarrhalis bronchitis
Acute bacterial bronchitis
Acute gonococcal cervicitis
Chlamydia Cervicitis
Gonorrhea
Haemophilus Influenzae Bronchitis
Haemophilus influenzae pneumonia
Moraxella Catarrhalis Pneumonia
Pneumonia due to Mycoplasma pneumoniae
Pneumonia due to Streptococcus
Streptococcus Pneumoniae Bronchitis
Urethritis due to Chlamydia trachomatis

Common side effects

No common side effects on file.

Drug interactions

saquinavir

Key clinical trials

Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tomefloxacin CI brief — competitive landscape report
Tomefloxacin updates RSS · CI watch RSS
Otsuka portfolio CI